{"id":"busilvex","rwe":[],"tags":[],"safety":{"commonSideEffects":[{"effect":"Fever","drugRate":"80%","severity":"serious"},{"effect":"Headache","drugRate":"69%","severity":"common"},{"effect":"Nausea","drugRate":"98%","severity":"serious"},{"effect":"Stomatitis","drugRate":"97%","severity":"serious"},{"effect":"Vomiting","drugRate":"95%","severity":"serious"},{"effect":"Anorexia","drugRate":"85%","severity":"serious"},{"effect":"Diarrhea","drugRate":"84%","severity":"serious"},{"effect":"Abdominal Pain","drugRate":"72%","severity":"serious"},{"effect":"Insomnia","drugRate":"84%","severity":"common"},{"effect":"Anxiety","drugRate":"72%","severity":"common"},{"effect":"Hypomagnesemia","drugRate":"77%","severity":"serious"},{"effect":"Hyperglycemia","drugRate":"66%","severity":"serious"},{"effect":"Hypokalemia","drugRate":"64%","severity":"serious"},{"effect":"Hyperbilirubinemia","drugRate":"49%","severity":"serious"},{"effect":"Hypocalcemia","drugRate":"49%","severity":"serious"},{"effect":"Edema","drugRate":"36%","severity":"common"},{"effect":"SGPT Elevation","drugRate":"31%","severity":"common"},{"effect":"Creatinine Increased","drugRate":"21%","severity":"common"},{"effect":"Rash","drugRate":"57%","severity":"common"},{"effect":"Pruritus","drugRate":"28%","severity":"common"},{"effect":"Pain","drugRate":"44%","severity":"common"},{"effect":"Tachycardia","drugRate":"44%","severity":"common"},{"effect":"Hypertension","drugRate":"36%","severity":"common"},{"effect":"Thrombosis","drugRate":"33%","severity":"common"},{"effect":"Vasodilation","drugRate":"25%","severity":"common"},{"effect":"Dizziness","drugRate":"30%","severity":"mild"},{"effect":"Depression","drugRate":"23%","severity":"mild"},{"effect":"Graft-versus-host disease","drugRate":"reported","severity":"unknown"},{"effect":"Infection","drugRate":"reported","severity":"unknown"},{"effect":"Pneumonia","drugRate":"3%","severity":"serious"}],"contraindications":["Anemia","Bacterial infectious disease","Breastfeeding (mother)","Epilepsy","Fanconi's anemia","Fibrosis of lung","Hyperglycemia","Hyperuricemia","Hypokalemia","Hypomagnesemia","Mycosis","Neutropenic disorder","Portal vein obstruction","Pregnancy, function","Radiation oncology AND/OR radiotherapy","Severe Bone Marrow Depression","Thrombocytopenic disorder","Viral disease"]},"trials":[],"_chembl":{"chemblId":"CHEMBL820","moleculeType":"Small molecule","molecularWeight":"246.31"},"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T16:50:18.838956","offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"Matrix metalloproteinase-9","modality":"Small Molecule"},"_scrapedAt":"2026-03-28T03:58:58.810Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Allogeneic bone marrow transplantation","diseaseId":"allogeneic-bone-marrow-transplantation","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Autologous hematopoietic stem-cell transplantation for Ewing's sarcoma family of tumors","diseaseId":"autologous-hematopoietic-stem-cell-transplantation-for-ewing's-sarcoma-family-of-tumors","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Malignant lymphoma","diseaseId":"malignant-lymphoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Neuroblastoma","diseaseId":"neuroblastoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Philadelphia Chromosome Positive Chronic Myelocytic Leukemia","diseaseId":"philadelphia-chromosome-positive-chronic-myelocytic-leukemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"_fixedFields":["sideEffects","modality→Small Molecule"],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02579967","phase":"PHASE2","title":"Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-11-19","conditions":"Primary T-cell Immunodeficiency Disorders, Common Variable Immunodeficiency, Immune System Diseases","enrollment":354},{"nctId":"NCT07113743","phase":"PHASE1, PHASE2","title":"Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease","status":"ENROLLING_BY_INVITATION","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-09-10","conditions":"Chronic Granulomatous Disease (CGD)","enrollment":10},{"nctId":"NCT01306019","phase":"PHASE1, PHASE2","title":"Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-09-25","conditions":"X-linked Severe Combined Immunodeficiency (XSCID)","enrollment":40},{"nctId":"NCT06954987","phase":"PHASE2","title":"Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-07-17","conditions":"Acute Myeloid Leukemia","enrollment":244},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT01176006","phase":"PHASE2","title":"Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-10-05","conditions":"DOCK8 Deficiency","enrollment":70},{"nctId":"NCT06959771","phase":"PHASE1, PHASE2","title":"Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-07-16","conditions":"CD40L-HyperIgM Syndrome","enrollment":1},{"nctId":"NCT05463133","phase":"PHASE1, PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-07-08","conditions":"Chronic Granulomatous Disease","enrollment":50},{"nctId":"NCT05951205","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/ βC Genotype","status":"WITHDRAWN","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2027-07-31","conditions":"Sickle Cell Disease","enrollment":""},{"nctId":"NCT06325709","phase":"PHASE1, PHASE2","title":"Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-04-17","conditions":"Chronic Granulomatous Disease (CGD), X-Linked Chronic Granulomatous Disease","enrollment":10},{"nctId":"NCT04990323","phase":"PHASE1, PHASE2","title":"US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies","status":"COMPLETED","sponsor":"ExCellThera inc.","startDate":"2021-12-01","conditions":"High Risk Myeloid Malignancies, Cord Blood Transplant","enrollment":13},{"nctId":"NCT03910452","phase":"EARLY_PHASE1","title":"Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-10-28","conditions":"Chronic Granulomatous Disease","enrollment":4},{"nctId":"NCT01861106","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-07-24","conditions":"GATA2, Immunodeficiency, MDS","enrollment":144},{"nctId":"NCT05477563","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-08-02","conditions":"Beta-Thalassemia, Thalassemia, Hematologic Diseases","enrollment":26},{"nctId":"NCT07101588","phase":"PHASE4","title":"Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-01-01","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)","enrollment":200},{"nctId":"NCT06816134","phase":"PHASE2","title":"Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-01-30","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Transplantation, Stem Cell","enrollment":48},{"nctId":"NCT04904588","phase":"PHASE2","title":"HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide","status":"ACTIVE_NOT_RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2021-09-30","conditions":"Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia","enrollment":300},{"nctId":"NCT03663933","phase":"PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-04","conditions":"Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Primary T-cell Immunodeficiency Disorders","enrollment":71},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT05436561","phase":"PHASE2","title":"Reduced MBF Regimen for Patients >=55 Years With Myeloid Malignancies","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2022-06-01","conditions":"Disease-free Survival","enrollment":61},{"nctId":"NCT03392987","phase":"PHASE2","title":"A Safety and Efficacy Study of Cryopreserved OTL-200 for Treatment of Metachromatic Leukodystrophy (MLD)","status":"COMPLETED","sponsor":"Orchard Therapeutics","startDate":"2018-01-25","conditions":"Lysosomal Storage Disease, Metachromatic Leukodystrophy","enrollment":10},{"nctId":"NCT06079879","phase":"PHASE3","title":"A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-31","conditions":"Essential Thrombocythemia","enrollment":340},{"nctId":"NCT04644016","phase":"PHASE2","title":"Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-11-20","conditions":"AML, ALL, MDS","enrollment":31},{"nctId":"NCT03970096","phase":"PHASE2","title":"Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-11-19","conditions":"Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":120},{"nctId":"NCT06872333","phase":"PHASE2","title":"Allo HSCT for High Risk Hemoglobinopathies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-11-19","conditions":"Graft Failure, Sickle Cell Disease, Hemoglobinopathies","enrollment":62},{"nctId":"NCT06345495","phase":"PHASE2","title":"High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-10-01","conditions":"Splenomegaly, Myelofibrosis","enrollment":30},{"nctId":"NCT01366612","phase":"PHASE3","title":"PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation","status":"TERMINATED","sponsor":"Hackensack Meridian Health","startDate":"2010-06-16","conditions":"Myeloid Malignancies, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia","enrollment":53},{"nctId":"NCT05329649","phase":"PHASE3","title":"Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-05-02","conditions":"Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea Intolerance","enrollment":13},{"nctId":"NCT04384692","phase":"PHASE2","title":"Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-12-18","conditions":"Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":53},{"nctId":"NCT02629120","phase":"PHASE1, PHASE2","title":"High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-12-17","conditions":"Chronic Granulomatous Disease Transplant","enrollment":45},{"nctId":"NCT05565105","phase":"PHASE2","title":"CD34+ Transplants for Leukemia and Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Guenther Koehne","startDate":"2026-06","conditions":"Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute","enrollment":100},{"nctId":"NCT05617625","phase":"PHASE2","title":"CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome","status":"SUSPENDED","sponsor":"Guenther Koehne","startDate":"2026-06","conditions":"Myelodysplastic Syndromes, Graft Vs Host Disease, Graft-versus-host-disease","enrollment":50},{"nctId":"NCT05356195","phase":"PHASE3","title":"Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-05-03","conditions":"Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn","enrollment":16},{"nctId":"NCT07441967","phase":"PHASE2","title":"The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-02-20","conditions":"Hematologic Malignancies","enrollment":44},{"nctId":"NCT03126916","phase":"PHASE3","title":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-14","conditions":"Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":750},{"nctId":"NCT05470491","phase":"PHASE1, PHASE2","title":"Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-01-26","conditions":"HIV, Hematologic Malignancies","enrollment":265},{"nctId":"NCT05589896","phase":"PHASE1, PHASE2","title":"A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies","status":"RECRUITING","sponsor":"Ossium Health, Inc.","startDate":"2024-08-16","conditions":"Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":12},{"nctId":"NCT05170828","phase":"PHASE1","title":"Cryopreserved MMUD BM With PTCy for Hematologic Malignancies","status":"WITHDRAWN","sponsor":"Ossium Health, Inc.","startDate":"2022-09","conditions":"Acute Leukemia, Myelodysplastic Syndromes, T-lymphoblastic Lymphoma","enrollment":""},{"nctId":"NCT06364774","phase":"PHASE1, PHASE2","title":"ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia","status":"RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2025-04-14","conditions":"Beta-Thalassemia","enrollment":12},{"nctId":"NCT03810196","phase":"NA","title":"CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT","status":"RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2019-03-01","conditions":"Acute Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":50},{"nctId":"NCT07228624","phase":"PHASE2","title":"Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-02-04","conditions":"Myelodysplastic/Myeloproliferative Neoplasm, Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":50},{"nctId":"NCT04708054","phase":"PHASE2, PHASE3","title":"Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-10-21","conditions":"Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome","enrollment":324},{"nctId":"NCT06207799","phase":"PHASE2","title":"Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-07-17","conditions":"Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy, Pre-transplant Purging","enrollment":40},{"nctId":"NCT05027945","phase":"PHASE2","title":"A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-02-23","conditions":"Immunodeficiency, Hematopoietic Stem Cell Transplantation","enrollment":54},{"nctId":"NCT02861417","phase":"PHASE2","title":"Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-08-05","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, High Risk Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome","enrollment":204},{"nctId":"NCT06851767","phase":"PHASE1, PHASE2","title":"Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy","status":"ENROLLING_BY_INVITATION","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-05-09","conditions":"X-linked Severe Combined Immunodeficiency, X-SCID, XSCID","enrollment":18},{"nctId":"NCT03619551","phase":"PHASE2","title":"Conditioning SCID Infants Diagnosed Early","status":"ACTIVE_NOT_RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2018-10-22","conditions":"SCID","enrollment":56},{"nctId":"NCT03538899","phase":"PHASE1, PHASE2","title":"Autologous Gene Therapy for Artemis-Deficient SCID","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2018-05-31","conditions":"Severe Combined Immunodeficiency","enrollment":24},{"nctId":"NCT06158828","phase":"PHASE1, PHASE2","title":"Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-05-15","conditions":"AML, Childhood, Aml, Acute Myeloid Leukemia, Pediatric","enrollment":68},{"nctId":"NCT01625351","phase":"PHASE1","title":"A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2012-08-20","conditions":"Ewing Sarcoma, Gastrointestinal Tumor, Germ Cell Tumor","enrollment":23},{"nctId":"NCT06001385","phase":"PHASE2","title":"HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2023-12-08","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia","enrollment":313},{"nctId":"NCT05917405","phase":"PHASE2","title":"Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2023-09-14","conditions":"Acute Myeloid Leukemia in Remission","enrollment":302},{"nctId":"NCT03579875","phase":"PHASE2","title":"Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2018-11-13","conditions":"Fanconi Anemia, Severe Aplastic Anemia, Myelodysplastic Syndromes","enrollment":48},{"nctId":"NCT07373639","phase":"","title":"A Long-term Follow-up Study in Patients Who Received BEAM-101","status":"RECRUITING","sponsor":"Beam Therapeutics Inc.","startDate":"2025-12-15","conditions":"Hemoglobinopathy, Sickle Cell Disease","enrollment":50},{"nctId":"NCT05327023","phase":"PHASE1, PHASE2","title":"Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-05-23","conditions":"Hematologic Neoplasms","enrollment":430},{"nctId":"NCT06252870","phase":"PHASE2","title":"Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-07-18","conditions":"Graft Versus Host Disease, Hematologic Malignancy","enrollment":82},{"nctId":"NCT01175356","phase":"PHASE1","title":"Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2011-12-21","conditions":"Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma","enrollment":99},{"nctId":"NCT01652092","phase":"NA","title":"Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2012-09-04","conditions":"SCID, Omenn's Syndrome, Reticular Dysgenesis","enrollment":57},{"nctId":"NCT03121014","phase":"PHASE2","title":"Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2017-04-24","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":38},{"nctId":"NCT02171104","phase":"PHASE2","title":"MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2014-07-10","conditions":"Mucopolysaccharidosis Disorders, Hurler Syndrome, Hunter Syndrome","enrollment":149},{"nctId":"NCT03674411","phase":"PHASE2","title":"Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2019-01-02","conditions":"Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Biphenotypic/Undifferentiated Leukemia","enrollment":22},{"nctId":"NCT03922724","phase":"PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-04-18","conditions":"Peripheral T-cell Lymphomas, Lymphoproliferative Disorders, Immune System Diseases","enrollment":330},{"nctId":"NCT03983850","phase":"PHASE1, PHASE2","title":"Optimizing PTCy Dose and Timing","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-09","conditions":"Graft Versus Host Disease, Hematologic Neoplasms","enrollment":105},{"nctId":"NCT03613532","phase":"PHASE1","title":"Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jacqueline Garcia, MD","startDate":"2018-10-24","conditions":"Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)","enrollment":102},{"nctId":"NCT06149403","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCT","status":"ACTIVE_NOT_RECRUITING","sponsor":"Orchard Therapeutics","startDate":"2023-12-11","conditions":"MPS-IH (Hurler Syndrome)","enrollment":41},{"nctId":"NCT05457556","phase":"PHASE3","title":"Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2023-03-15","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia","enrollment":435},{"nctId":"NCT03655678","phase":"PHASE2, PHASE3","title":"A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-09-14","conditions":"Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn","enrollment":59},{"nctId":"NCT05456880","phase":"PHASE1, PHASE2","title":"BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beam Therapeutics Inc.","startDate":"2022-08-30","conditions":"Sickle Cell Disease","enrollment":15},{"nctId":"NCT01349101","phase":"PHASE2","title":"A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2011-02-10","conditions":"Hematological Malignancies","enrollment":78},{"nctId":"NCT03247088","phase":"PHASE1, PHASE2","title":"Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-07-30","conditions":"Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":74},{"nctId":"NCT03311503","phase":"PHASE1, PHASE2","title":"Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning","status":"RECRUITING","sponsor":"David Williams","startDate":"2018-02-26","conditions":"Severe Combined Immunodeficiency, X Linked, Gene Therapy","enrollment":12},{"nctId":"NCT07276737","phase":"PHASE2","title":"Preconditioning With a Combination of Thiotepa, Cyclophosphamide, and Busulfan for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of NK/T-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2025-12-30","conditions":"NK T-Cell Lymphoma","enrollment":37},{"nctId":"NCT02349906","phase":"PHASE2","title":"Treosulfan-based Versus Busulfan-based Conditioning in Paediatric Patients With Non-malignant Diseases","status":"COMPLETED","sponsor":"medac GmbH","startDate":"2015-04","conditions":"Primary Immunodeficiencies, Inborn Errors of Metabolism, Haemoglobinopathies","enrollment":106},{"nctId":"NCT02251821","phase":"PHASE2","title":"JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2014-10-20","conditions":"Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":61},{"nctId":"NCT00534469","phase":"PHASE2","title":"Auto BMT for Non-M3 AML in 1st Remission in Pts